Copyright 2024 All rights reserved.
PR Center
Development of safe stem cell therapy for
immune rejection
We are working to improve
the quality of life in various fields.
PR Center
IP Portfolio
| Title | Regi/App No. (Date) | Remarks |
|---|---|---|
|
Production Methods of Immune-tolerant Extracellular Vesicle containing Lactate Dehydrogenase B and Peroxisome proliferator-activated receptor gamma coactivator 1-alpha and Therapeutic Composition for Anti-Cancer thereof
Regi/App No. (Date) 7261510 (2023.04.12)
Remarks JP Registered
|
7261510 (2023.04.12) | JP Registered |
|
Production Methods of Immune-tolerant Extracellular Vesicle containing Lactate Dehydrogenase B and Peroxisome proliferator-activated receptor gamma coactivator 1-alpha and Therapeutic Composition for Anti-Cancer thereof
Regi/App No. (Date) 17,611,046 (2023.07)
Remarks US Registered
|
17,611,046 (2023.07) | US Registered |
|
Production Methods of Immune-tolerant Extracellular Vesicles containing Fetal-derived Primal Immunoglobulins
Regi/App No. (Date) 10-2252325 (2021.05.10)
Remarks KR Registered
|
10-2252325 (2021.05.10) | KR Registered |
|
Production Methods of Immune-tolerant Extracellular Vesicles containing Fetal-derived Primal Immunoglobulins
Regi/App No. (Date) PCT/KR2021/009189 (2021.07.16)
Remarks PCT Applied
|
PCT/KR2021/009189 (2021.07.16) | PCT Applied |
|
Production Methods of Immune-tolerant Extracellular Vesicles containing Fetal-derived Primal Immunoglobulins
Regi/App No. (Date) 17,923,871 (2022.11.07)
Remarks US Applied
|
17,923,871 (2022.11.07) | US Applied |
|
Production Methods of Immune-tolerant Extracellular Vesicles containing Fetal-derived Primal Immunoglobulins
Regi/App No. (Date) 2022-568383 (2022.11.07)
Remarks JP Applied
|
2022-568383 (2022.11.07) | JP Applied |